Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Dec
15
Today In Oncology
Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer
Mobile Health Intervention Offers Tailored Support for Adolescent and Young Adult Breast Cancer Survivors
Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer
Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML
Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo